CR20230452A - Composiciones que contienen análogos de incretina y usos de estas - Google Patents
Composiciones que contienen análogos de incretina y usos de estasInfo
- Publication number
- CR20230452A CR20230452A CR20230452A CR20230452A CR20230452A CR 20230452 A CR20230452 A CR 20230452A CR 20230452 A CR20230452 A CR 20230452A CR 20230452 A CR20230452 A CR 20230452A CR 20230452 A CR20230452 A CR 20230452A
- Authority
- CR
- Costa Rica
- Prior art keywords
- containing compositions
- incretin analog
- incretin
- dyslipidemia
- obesity
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 239000012929 tonicity agent Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporciona una composición que incluye un análogo de incretina con actividad en cada uno de los receptores de polipéptido insulinotrópico dependiente de glucosa (GIP), de péptido similar al glucagón tipo 1 (GLP-1) y de glucagón (GCG) (es decir, agonista triple de receptores) y uno o más agentes adicionales como un agente de tonicidad y un conservante. También se proporcionan métodos para tratar enfermedades como la diabetes mellitus tipo 2, la dislipidemia, el síndrome metabólico, la enfermedad de hígado graso no alcohólica, la esteatohepatitis no alcohólica y la obesidad con la composición.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164702P | 2021-03-23 | 2021-03-23 | |
| PCT/US2022/021309 WO2022204117A1 (en) | 2021-03-23 | 2022-03-22 | Incretin analog-containing compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230452A true CR20230452A (es) | 2023-10-11 |
Family
ID=81580297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230452A CR20230452A (es) | 2021-03-23 | 2022-03-22 | Composiciones que contienen análogos de incretina y usos de estas |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20240173250A1 (es) |
| EP (1) | EP4312982A1 (es) |
| JP (1) | JP2024513754A (es) |
| KR (1) | KR20230146645A (es) |
| CN (1) | CN117042754A (es) |
| AR (1) | AR125086A1 (es) |
| AU (1) | AU2022246002A1 (es) |
| BR (1) | BR112023016083A2 (es) |
| CA (1) | CA3213230A1 (es) |
| CO (1) | CO2023012373A2 (es) |
| CR (1) | CR20230452A (es) |
| DO (1) | DOP2023000200A (es) |
| EC (1) | ECSP23071867A (es) |
| IL (1) | IL305688A (es) |
| MX (1) | MX2023011278A (es) |
| PE (1) | PE20240238A1 (es) |
| TW (1) | TWI837615B (es) |
| WO (1) | WO2022204117A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101193652B (zh) * | 2005-04-08 | 2011-11-02 | 安米林药品公司 | 包含肠降血糖素肽和非质子极性溶剂的药物制剂 |
| PE20080840A1 (es) * | 2006-09-13 | 2008-08-27 | Smithkline Beecham Corp | Metodos para administrar agentes hipoglucemiantes de larga duracion |
| CN101516391A (zh) * | 2006-09-13 | 2009-08-26 | 史密丝克莱恩比彻姆公司 | 施用长效降血糖药的方法 |
| DK2542280T3 (da) | 2010-03-01 | 2014-10-20 | Lilly Co Eli | Automatisk injektionsanordning med forsinkelsesmekanisme indbefattende dobbeltfungerende forspændingselement |
| KR20130101515A (ko) * | 2010-08-23 | 2013-09-13 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디. | 위에 활성제를 전달하기 위한 조성물 |
| BR112014014898A2 (pt) * | 2011-12-22 | 2020-10-27 | Pfizer Inc. | processo para purificar uma amostra de anticorpo h38c2, ou variante do mesmo, e composição compreendendo o referido h38c2 |
| MX2015002985A (es) * | 2012-09-07 | 2015-06-22 | Sanofi Sa | Proteinas de fusion para el tratamiento de un sindrome metabolico. |
| WO2018213151A1 (en) * | 2017-05-18 | 2018-11-22 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation comprising incretin-insulin conjugates |
| TWI809515B (zh) | 2017-12-21 | 2023-07-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TWI810937B (zh) | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| AU2019311000B2 (en) * | 2018-07-23 | 2023-02-02 | Eli Lilly And Company | GIP/GLP1 co-agonist compounds |
-
2022
- 2022-03-15 AR ARP220100594A patent/AR125086A1/es unknown
- 2022-03-15 TW TW111109488A patent/TWI837615B/zh active
- 2022-03-22 CR CR20230452A patent/CR20230452A/es unknown
- 2022-03-22 WO PCT/US2022/021309 patent/WO2022204117A1/en active Application Filing
- 2022-03-22 CA CA3213230A patent/CA3213230A1/en active Pending
- 2022-03-22 CN CN202280023411.5A patent/CN117042754A/zh active Pending
- 2022-03-22 KR KR1020237032194A patent/KR20230146645A/ko active Search and Examination
- 2022-03-22 PE PE2023002682A patent/PE20240238A1/es unknown
- 2022-03-22 BR BR112023016083A patent/BR112023016083A2/pt unknown
- 2022-03-22 EP EP22721153.9A patent/EP4312982A1/en active Pending
- 2022-03-22 US US18/552,013 patent/US20240173250A1/en active Pending
- 2022-03-22 AU AU2022246002A patent/AU2022246002A1/en active Pending
- 2022-03-22 IL IL305688A patent/IL305688A/en unknown
- 2022-03-22 JP JP2023558406A patent/JP2024513754A/ja active Pending
- 2022-03-22 MX MX2023011278A patent/MX2023011278A/es unknown
-
2023
- 2023-09-19 CO CONC2023/0012373A patent/CO2023012373A2/es unknown
- 2023-09-20 DO DO2023000200A patent/DOP2023000200A/es unknown
- 2023-09-22 EC ECSENADI202371867A patent/ECSP23071867A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023012373A2 (es) | 2023-09-29 |
| CN117042754A (zh) | 2023-11-10 |
| DOP2023000200A (es) | 2023-10-15 |
| US20240173250A1 (en) | 2024-05-30 |
| IL305688A (en) | 2023-11-01 |
| AU2022246002A1 (en) | 2023-08-24 |
| JP2024513754A (ja) | 2024-03-27 |
| WO2022204117A1 (en) | 2022-09-29 |
| PE20240238A1 (es) | 2024-02-16 |
| MX2023011278A (es) | 2023-10-04 |
| TWI837615B (zh) | 2024-04-01 |
| CA3213230A1 (en) | 2022-09-29 |
| KR20230146645A (ko) | 2023-10-19 |
| ECSP23071867A (es) | 2023-11-30 |
| TW202302139A (zh) | 2023-01-16 |
| BR112023016083A2 (pt) | 2023-10-03 |
| EP4312982A1 (en) | 2024-02-07 |
| AR125086A1 (es) | 2023-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021012492A (es) | Agonistas de glp-1r y usos de los mismos. | |
| EA202191432A1 (ru) | Агонисты glp-1r и их применения | |
| PH12015502617A1 (en) | Combinations comprising a fungicidal a strain and an active compound | |
| EA201390497A1 (ru) | Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия | |
| BRPI0409100A (pt) | composição conservante de madeira, e, métodos para conservar um produto de madeira e madeira | |
| WO2008092006A3 (en) | Antimicrobial compositions | |
| EP1640000A3 (de) | Pharmazeutische Zusammensetzung aus einem beta-3-Adrenozeptor-Agonisten und einem Serotonin- und/oder Norepinephrin-Reuptake-Inhibitor | |
| HRP20070539T3 (en) | Synergistic antifungal ddac compositions | |
| PE20081350A1 (es) | Sal fumarato de (alfas s, beta r)-6-bromo-alfa-[2(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol | |
| EP1755388A4 (en) | MIXED CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | |
| WO2006076065A3 (en) | Personal care compositions | |
| UA93714C2 (ru) | Комбинация активных веществ c инсектицидным действием, применение комбинации kak средства для борьбы c вредителями | |
| BRPI0606191A2 (pt) | compostos de amino e carboxamido tetracìclicos e métodos do seu uso | |
| MX2020009935A (es) | Formulaciones acuosas y estables de anticuerpos anti-tau. | |
| MX2022003251A (es) | Anticuerpo contra gipr y su proteina de fusion con glp-1, y composicion farmaceutica y aplicacion de los mismos. | |
| MX2023008330A (es) | Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos. | |
| CR20230452A (es) | Composiciones que contienen análogos de incretina y usos de estas | |
| MX2021002902A (es) | Composicion farmaceutica para prevenir o tratar la enfermedad del higado graso no alcoholico, que contiene ligando gpr119 como principio activo. | |
| WO2004087076A3 (en) | Methods for inhibiting adipogenesis and for treating type 2 diabetes | |
| MX2020013510A (es) | Composiciones para tratamiento, y metodos para fabricar y usar las mismas. | |
| FR2931661B1 (fr) | Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise et un retinoide. | |
| UA92444C2 (uk) | Фунгіцидна суміш тритиконазолу і дифеноконазолу, композиція на її основі та спосіб боротьби зі шкідливими фітопатогенними грибами | |
| BRPI0506793A (pt) | métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5 | |
| TW200628167A (en) | Composition for preventing and/or treating metabolic syndrome and insulin resistance syndrome | |
| BRPI0406734A (pt) | Composição termiticida, e, método para controlar térmitas |